Join Date
October 2024
Gender
Not Specified
Age
Not Specified
About Kathryn Kwant
Kathryn has 12 years of experience engineering proteins for improved properties. She spent 5 years as a key early scientist at Harpoon Therapeutics, where she developed bispecific immunotherapies and protease activated immunotherapies. She has helped develop multiple drugs that are currently in the clinic to treat various cancers and has multiple patents and patent applications.
Companies & Work
Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.
Engage’s Tethosome platform solves the two key hurdles that have held back the field of non-viral DNA: potency and toxicity. Using proven LNP technology, we deliver a therapeutic DNA and an mRNA encoding our proprietary Tethosome protein. This protein localizes DNA to the nucleus, increasing expression by over 100-fold. Critically, our Tethosome platform is invisible to immune sensors which detect foreign DNA and which can cause lethal immune reactions. This allows us to safely deliver potent DNA, re-dose when needed, and titrate expression to optimal levels.
Engage’s Tethosome platform solves the two key hurdles that have held back the field of non-viral DNA: potency and toxicity. Using proven LNP technology, we deliver a therapeutic DNA and an mRNA encoding our proprietary Tethosome protein. This protein localizes DNA to the nucleus, increasing expression by over 100-fold. Critically, our Tethosome platform is invisible to immune sensors which detect foreign DNA and which can cause lethal immune reactions. This allows us to safely deliver potent DNA, re-dose when needed, and titrate expression to optimal levels.
